Mice treated with liraglutide, an injectable GLP-1 receptor agonist (GLP-1 RA) used in the treatment of T2D, with demonstrated efficacy in improving glycemic control, has been shown to produce substantial changes in the gut microbiota assessed with pyrosequencing of 16S rRNA with enrichment of several genera, of whom Desulfovibrio (40). This evidence concerns the gene GCG and type 2 diabetes mellitus.